SCHEMBL1889264

SCHEMBL1889264

O=c1[nH]c2c(-c3ccccc3)c(C(F)(F)F)sc2c(=O)n1O

nearest known ligand 0.53

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ FEN1 P39748 14/20 0.53
▸ ERCC5 P28715 6/20 0.53
▸ ERCC1 P07992 2/20 0.53
▸ ERCC4 Q92889 2/20 0.53
▸ PIM1 P11309 1/20 0.45
▸ PIM3 Q86V86 1/20 0.45
▸ CLK4 Q9HAZ1 1/20 0.45
▸ CA12 O43570 1/20 0.37
▸ CA9 Q16790 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1886589 0.70 FEN1 (1.00) FEN1ERCC5ERCC1ERCC4CA12
SCHEMBL1884682 0.69 FEN1 (1.00) FEN1ERCC5ERCC1ERCC4CA12
SCHEMBL13856858 0.68 PIM1 (0.47) PIM1PIM3CLK4
SCHEMBL1884360 0.67 FEN1 (1.00) FEN1ERCC5ERCC1ERCC4CA12
SCHEMBL18670454 0.63 FEN1 (1.00) FEN1ERCC5ERCC1ERCC4CA12
SCHEMBL29960340 0.63 FEN1 (1.00) FEN1ERCC5ERCC1ERCC4CA12
SCHEMBL12661603 0.61 FEN1 (1.00) FEN1ERCC5ERCC1ERCC4CA12
SCHEMBL1894366 0.60 FEN1 (1.00) FEN1ERCC5ERCC1ERCC4
SCHEMBL18670352 0.60 FEN1 (1.00) FEN1ERCC5ERCC1ERCC4CA12
SCHEMBL29959667 0.60 FEN1 (1.00) FEN1ERCC5ERCC1ERCC4CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947691-B2 Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof ATHERSYS, INC. (US) 2011-05-24 — — US claimed
US-20080287465-A1 Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof ATHERSYS, INC. (US) 2008-11-20 — — US claimed
WO-2006014647-A2 CYCLIC N-HYDROXY IMIDES AS INHIBITORS OF FLAP ENDONUCLEASE AND USES THEREOF ATHERSYS, INC. (US) 2006-02-09 — — WO claimed
US-7947691-B2 Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof ATHERSYS, INC. (US) 2011-05-24 — — US disclosed
US-7947691-B2 Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof ATHERSYS, INC. (US) 2011-05-24 — — US disclosed
US-7947691-B2 Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof ATHERSYS, INC. (US) 2011-05-24 — — US disclosed
US-20080287465-A1 Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof ATHERSYS, INC. (US) 2008-11-20 — — US disclosed
US-20080287465-A1 Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof ATHERSYS, INC. (US) 2008-11-20 — — US disclosed
US-20080287465-A1 Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof ATHERSYS, INC. (US) 2008-11-20 — — US disclosed
WO-2006014647-A2 CYCLIC N-HYDROXY IMIDES AS INHIBITORS OF FLAP ENDONUCLEASE AND USES THEREOF ATHERSYS, INC. (US) 2006-02-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287465-A1 Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof FEN1, UNG, POLH FEN1 1/4885ERCC5 73/4885ERCC1 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback